[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Human Papillomavirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

May 2024 | 133 pages | ID: H97366AB0703EN
IMARC Group

US$ 6,499.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The 7 major human papillomavirus markets are expected to exhibit a CAGR of 8.33% during 2024-2034.

The human papillomavirus market has been comprehensively analyzed in IMARC's new report titled "Human Papillomavirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Human papillomavirus (HPV) refers to a common sexually transmitted infection that affects both men and women. It is mainly characterized by the presence of skin or mucous membrane growths (warts) in various parts of the body. The disease is primarily spread through skin-to-skin contact or sexual intercourse, including vaginal, anal, and oral sex. Some of the common symptoms associated with HPV are itching, discomfort, pain, breathing difficulty, a burning sensation in the affected area, etc. This ailment can also increase the likelihood of penile, cervical, vaginal, vulvar, anal, mouth, and throat cancers. The diagnosis of the illness typically involves a combination of clinical examination, medical history, and specific investigations. A healthcare provider may perform a visual inspection of the affected areas to look for any signs of HPV infection, such as genital warts. Additionally, a pap smear test is also utilized to detect abnormal cervical cells that might be causing the underlying indications. If there are suspicious lesions, a tissue biopsy is further recommended to evaluate the type and severity of the ailment.

The increasing cases of unprotected sex or skin damage, which can enhance the risk of viral transmission among individuals, are primarily driving the human papillomavirus market. In addition to this, the rising incidences of weakened immune systems due to HIV/AIDS, chronic lifestyle disorders, the use of immunosuppressant medications, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of loop electrosurgical excision procedure, which utilizes a thin wire loop heated by an electrical current to excise the affected tissue while causing minimal damage to surrounding healthy cells, is further bolstering the market growth. Apart from this, the inflating application of topical therapeutic agents containing imiquimod or podophyllin to stimulate the production of cytokines, like interferon-alpha, that can enhance the immune response against HPV infection is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cryotherapy on account of its numerous advantages over conventional surgeries, such as targeted destruction of lesions and reduced risk of noticeable scarring, is expected to drive the human papillomavirus market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the human papillomavirus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for human papillomavirus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the human papillomavirus market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the human papillomavirus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the human papillomavirus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current human papillomavirus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the human papillomavirus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the human papillomavirus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the human papillomavirus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of human papillomavirus across the seven major markets?
What is the number of prevalent cases (2018-2034) of human papillomavirus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of human papillomavirus by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with human papillomavirus across the seven major markets?
What is the size of the human papillomavirus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of human papillomavirus?
What will be the growth rate of patients across the seven major markets?

Human Papillomavirus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for human papillomavirus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the human papillomavirus market?
What are the key regulatory events related to the human papillomavirus market?
What is the structure of clinical trial landscape by status related to the human papillomavirus market?
What is the structure of clinical trial landscape by phase related to the human papillomavirus market?
What is the structure of clinical trial landscape by route of administration related to the human papillomavirus market?
1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 HUMAN PAPILLOMAVIRUS - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 HUMAN PAPILLOMAVIRUS - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 HUMAN PAPILLOMAVIRUS - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
  7.2.1 Epidemiology Scenario (2018-2023)
  7.2.2 Epidemiology Forecast (2024-2034)
  7.2.3 Epidemiology by Age (?2018-2034?)
  7.2.4 Epidemiology by Gender (?2018-2034?)
  7.2.5 Diagnosed Cases (?2018-2034?)
  7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
  7.3.1 Epidemiology Scenario (2018-2023)
  7.3.2 Epidemiology Forecast (2024-2034)
  7.3.3 Epidemiology by Age (?2018-2034?)
  7.3.4 Epidemiology by Gender (?2018-2034?)
  7.3.5 Diagnosed Cases (?2018-2034?)
  7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
  7.4.1 Epidemiology Scenario (2018-2023)
  7.4.2 Epidemiology Forecast (2024-2034)
  7.4.3 Epidemiology by Age (?2018-2034?)
  7.4.4 Epidemiology by Gender (?2018-2034?)
  7.4.5 Diagnosed Cases (?2018-2034?)
  7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
  7.5.1 Epidemiology Scenario (2018-2023)
  7.5.2 Epidemiology Forecast (2024-2034)
  7.5.3 Epidemiology by Age (?2018-2034?)
  7.5.4 Epidemiology by Gender (?2018-2034?)
  7.5.5 Diagnosed Cases (?2018-2034?)
  7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
  7.6.1 Epidemiology Scenario (2018-2023)
  7.6.2 Epidemiology Forecast (2024-2034)
  7.6.3 Epidemiology by Age (?2018-2034?)
  7.6.4 Epidemiology by Gender (?2018-2034?)
  7.6.5 Diagnosed Cases (?2018-2034?)
  7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
  7.7.1 Epidemiology Scenario (2018-2023)
  7.7.2 Epidemiology Forecast (2024-2034)
  7.7.3 Epidemiology by Age (?2018-2034?)
  7.7.4 Epidemiology by Gender (?2018-2034?)
  7.7.5 Diagnosed Cases (?2018-2034?)
  7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
  7.8.1 Epidemiology Scenario (2018-2023)
  7.8.2 Epidemiology Forecast (2024-2034)
  7.8.3 Epidemiology by Age (?2018-2034?)
  7.8.4 Epidemiology by Gender (?2018-2034?)
  7.8.5 Diagnosed Cases (?2018-2034?)
  7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
  7.9.1 Epidemiology Scenario (2018-2023)
  7.9.2 Epidemiology Forecast (2024-2034)
  7.9.3 Epidemiology by Age (?2018-2034?)
  7.9.4 Epidemiology by Gender (?2018-2034?)
  7.9.5 Diagnosed Cases (?2018-2034?)
  7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 HUMAN PAPILLOMAVIRUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 HUMAN PAPILLOMAVIRUS - UNMET NEEDS

10 HUMAN PAPILLOMAVIRUS - KEY ENDPOINTS OF TREATMENT

11 HUMAN PAPILLOMAVIRUS - MARKETED PRODUCTS

11.1 List of Human Papillomavirus Marketed Drugs Across the Top 7 Markets
  11.1.1 Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) - Merck & Co.
    11.1.1.1 Drug Overview
    11.1.1.2 Mechanism of Action
    11.1.1.3 Regulatory Status
    11.1.1.4 Clinical Trial Results
    11.1.1.5 Sales Across Major Markets
  11.1.2 Cervarix (Human papillomavirus vaccine recombinant bivalent) - GlaxoSmithKline
    11.1.2.1 Drug Overview
    11.1.2.2 Mechanism of Action
    11.1.2.3 Regulatory Status
    11.1.2.4 Clinical Trial Results
    11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 HUMAN PAPILLOMAVIRUS - PIPELINE DRUGS

12.1 List of Human Papillomavirus Pipeline Drugs Across the Top 7 Markets
  12.1.1 Drug Name - Company Name
    12.1.1.1 Drug Overview
    12.1.1.2 Mechanism of Action
    12.1.1.3 Clinical Trial Results
    12.1.1.4 Safety and Efficacy
    12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.

13. HUMAN PAPILLOMAVIRUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. HUMAN PAPILLOMAVIRUS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 HUMAN PAPILLOMAVIRUS - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
  15.2.1 Human Papillomavirus - Market Size
    15.2.1.1 Market Size (2018-2023)
    15.2.1.2 Market Forecast (2024-2034)
  15.2.2 Human Papillomavirus - Market Size by Therapies
    15.2.2.1 Market Size by Therapies (2018-2023)
    15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
  15.3.1 Human Papillomavirus - Market Size
    15.3.1.1 Market Size (2018-2023)
    15.3.1.2 Market Forecast (2024-2034)
  15.3.2 Human Papillomavirus - Market Size by Therapies
    15.3.2.1 Market Size by Therapies (2018-2023)
    15.3.2.2 Market Forecast by Therapies (2024-2034)
  15.3.3 Human Papillomavirus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
  15.4.1 Human Papillomavirus - Market Size
    15.4.1.1 Market Size (2018-2023)
    15.4.1.2 Market Forecast (2024-2034)
  15.4.2 Human Papillomavirus - Market Size by Therapies
    15.4.2.1 Market Size by Therapies (2018-2023)
    15.4.2.2 Market Forecast by Therapies (2024-2034)
  15.4.3 Human Papillomavirus - Access and Reimbursement Overview
15.5 Market Scenario - France
  15.5.1 Human Papillomavirus - Market Size
    15.5.1.1 Market Size (2018-2023)
    15.5.1.2 Market Forecast (2024-2034)
  15.5.2 Human Papillomavirus - Market Size by Therapies
    15.5.2.1 Market Size by Therapies (2018-2023)
    15.5.2.2 Market Forecast by Therapies (2024-2034)
  15.5.3 Human Papillomavirus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
  15.6.1 Human Papillomavirus - Market Size
    15.6.1.1 Market Size (2018-2023)
    15.6.1.2 Market Forecast (2024-2034)
  15.6.2 Human Papillomavirus - Market Size by Therapies
    15.6.2.1 Market Size by Therapies (2018-2023)
    15.6.2.2 Market Forecast by Therapies (2024-2034)
  15.6.3 Human Papillomavirus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
  15.7.1 Human Papillomavirus - Market Size
    15.7.1.1 Market Size (2018-2023)
    15.7.1.2 Market Forecast (2024-2034)
  15.7.2 Human Papillomavirus - Market Size by Therapies
    15.7.2.1 Market Size by Therapies (2018-2023)
    15.7.2.2 Market Forecast by Therapies (2024-2034)
  15.7.3 Human Papillomavirus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
  15.8.1 Human Papillomavirus - Market Size
    15.8.1.1 Market Size (2018-2023)
    15.8.1.2 Market Forecast (2024-2034)
  15.8.2 Human Papillomavirus - Market Size by Therapies
    15.8.2.1 Market Size by Therapies (2018-2023)
    15.8.2.2 Market Forecast by Therapies (2024-2034)
  15.8.3 Human Papillomavirus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
  15.9.1 Human Papillomavirus - Market Size
    15.9.1.1 Market Size (2018-2023)
    15.9.1.2 Market Forecast (2024-2034)
  15.9.2 Human Papillomavirus - Market Size by Therapies
    15.9.2.1 Market Size by Therapies (2018-2023)
    15.9.2.2 Market Forecast by Therapies (2024-2034)
  15.9.3 Human Papillomavirus - Access and Reimbursement Overview

16 HUMAN PAPILLOMAVIRUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 HUMAN PAPILLOMAVIRUS MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 HUMAN PAPILLOMAVIRUS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX


More Publications